Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Collegium Pharmaceutical (COLL) Cash from Investing Activities (2016 - 2025)

Collegium Pharmaceutical (COLL) has 10 years of Cash from Investing Activities data on record, last reported at -$20.1 million in Q4 2025.

  • For Q4 2025, Cash from Investing Activities fell 70.63% year-over-year to -$20.1 million; the TTM value through Dec 2025 reached -$63.5 million, up 77.92%, while the annual FY2025 figure was -$63.5 million, 77.92% up from the prior year.
  • Cash from Investing Activities reached -$20.1 million in Q4 2025 per COLL's latest filing, up from -$30.9 million in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at -$113000.0 in Q3 2022 and bottomed at -$572.2 million in Q1 2022.
  • Average Cash from Investing Activities over 5 years is -$49.9 million, with a median of -$6.4 million recorded in 2023.
  • Peak YoY movement for Cash from Investing Activities: tumbled 133586.21% in 2022, then soared 99.97% in 2023.
  • A 5-year view of Cash from Investing Activities shows it stood at -$515000.0 in 2021, then crashed by 82.52% to -$940000.0 in 2022, then crashed by 2569.89% to -$25.1 million in 2023, then surged by 53.13% to -$11.8 million in 2024, then crashed by 70.63% to -$20.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Investing Activities were -$20.1 million in Q4 2025, -$30.9 million in Q3 2025, and -$2.9 million in Q2 2025.